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Updated analysis of KEYNOTE-024: Pembrolizumab versus platinumbased chemotherapy for advanced non-small-cell lung cancer with PD-L1
tumor proportion score of 50% or greater
Abstract

PURPOSE In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly
improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in
patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed death
ligand 1 tumor proportion score of 50% or greater and without EGFR/ALK aberrations. We report an
updated OS and tolerability analysis, including analyses adjusting for potential bias introduced by crossover
from chemotherapy to pembrolizumab.
PATIENTS AND METHODS Patients were randomly assigned to pembrolizumab 200 mg every 3 weeks
(for up to 2 years) or investigator's choice of platinum-based chemotherapy (four to six cycles). Patients
assigned to chemotherapy could cross over to pembrolizumab upon meeting eligibility criteria. The primary
end point was progression-free survival; OS was an important key secondary end point. Crossover adjustment
analysis was done using the following three methods: simplified two-stage method, rank-preserving structural
failure time, and inverse probability of censoring weighting.
RESULTS Three hundred five patients were randomly assigned (pembrolizumab, n = 154; chemotherapy, n =
151). At data cutoff ( July 10, 2017; median follow-up, 25.2 months), 73 patients in the pembrolizumab arm
and 96 in the chemotherapy arm had died. Median OS was 30.0 months (95% CI, 18.3 months to not
reached) with pembrolizumab and 14.2 months (95% CI, 9.8 to 19.0 months) with chemotherapy (hazard
ratio, 0.63; 95% CI, 0.47 to 0.86). Eighty-two patients assigned to chemotherapy crossed over on study to
receive pembrolizumab. When adjusted for crossover using the two-stage method, the hazard ratio for OS for
pembrolizumab versus chemotherapy was 0.49 (95% CI, 0.34 to 0.69); results using rank-preserving
structural failure time and inverse probability of censoring weighting were similar. Treatment-related grade 3
to 5 adverse events were less frequent with pembrolizumab compared with chemotherapy (31.2% v 53.3%,
respectively).
CONCLUSION With prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate
an OS benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/
ALK aberrations, despite crossover from the control arm to pembrolizumab as subsequent therapy.
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abstract

PURPOSE In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab signiﬁcantly improved
progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with
previously untreated advanced non–small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor
proportion score of 50% or greater and without EGFR/ALK aberrations. We report an updated OS and tolerability
analysis, including analyses adjusting for potential bias introduced by crossover from chemotherapy to
pembrolizumab.
PATIENTS AND METHODS Patients were randomly assigned to pembrolizumab 200 mg every 3 weeks (for up to
2 years) or investigator’s choice of platinum-based chemotherapy (four to six cycles). Patients assigned to
chemotherapy could cross over to pembrolizumab upon meeting eligibility criteria. The primary end point was
progression-free survival; OS was an important key secondary end point. Crossover adjustment analysis was
done using the following three methods: simpliﬁed two-stage method, rank-preserving structural failure time,
and inverse probability of censoring weighting.
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RESULTS Three hundred ﬁve patients were randomly assigned (pembrolizumab, n = 154; chemotherapy, n =
151). At data cutoff (July 10, 2017; median follow-up, 25.2 months), 73 patients in the pembrolizumab arm and
96 in the chemotherapy arm had died. Median OS was 30.0 months (95% CI, 18.3 months to not reached) with
pembrolizumab and 14.2 months (95% CI, 9.8 to 19.0 months) with chemotherapy (hazard ratio, 0.63; 95% CI,
0.47 to 0.86). Eighty-two patients assigned to chemotherapy crossed over on study to receive pembrolizumab.
When adjusted for crossover using the two-stage method, the hazard ratio for OS for pembrolizumab versus
chemotherapy was 0.49 (95% CI, 0.34 to 0.69); results using rank-preserving structural failure time and inverse
probability of censoring weighting were similar. Treatment-related grade 3 to 5 adverse events were less frequent
with pembrolizumab compared with chemotherapy (31.2% v 53.3%, respectively).
CONCLUSION With prolonged follow-up, ﬁrst-line pembrolizumab monotherapy continues to demonstrate an OS
beneﬁt over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations, despite crossover from the control arm to pembrolizumab as subsequent therapy.
J Clin Oncol 37:537-546. © 2019 by American Society of Clinical Oncology

INTRODUCTION
KEYNOTE-024 (ClinicalTrials.gov identiﬁer: NCT02142738)
is an international, randomized, open-label, phase III
study of pembrolizumab monotherapy versus platinumbased chemotherapy in patients with previously
untreated advanced non–small-cell lung cancer
(NSCLC) with programmed death ligand 1 (PD-L1)
tumor proportion score (TPS) of 50% or greater and
without EGFR mutation or ALK translocation.1 At the

second preplanned interim analysis (median followup, 11.2 months), pembrolizumab was associated
with signiﬁcantly improved progression-free survival
(PFS; hazard ratio [HR], 0.50; 95% CI, 0.37 to 0.68;
one-sided P , .001) and overall survival (OS; HR,
0.60; 95% CI, 0.41 to 0.89; one-sided P = .005).
Median OS was not reached (NR) in either arm.
Importantly, pembrolizumab was generally well tolerated. On the basis of these results, the independent
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data and safety monitoring committee recommended the
trial be stopped early to allow for use of pembrolizumab
in patients randomly assigned to chemotherapy. The
improvement in OS occurred despite the study design
allowing patients randomly assigned to chemotherapy to
cross over to pembrolizumab. The observed treatment
effect was potentially attenuated because many patients
participated in this crossover.

revealed superiority, only patients with progressive disease
conﬁrmed by blinded, independent, central radiology
review were eligible. The protocol did not include preplanned crossover from pembrolizumab to chemotherapy
or postprogression treatment guidelines for pembrolizumab
recipients. Patients in either arm who were clinically stable
and considered by the investigator to be deriving clinical
beneﬁt could continue therapy after disease progression.

We report an updated analysis of OS and other efﬁcacy and
safety outcomes after a median follow-up of 25.2 months.
In addition, we describe outcomes among patients who
crossed over from chemotherapy to pembrolizumab per
protocol and analyses that adjusted for potential bias
introduced by treatment crossover.

The primary end point was PFS (time since random
assignment to disease progression or death from any
cause, whichever occurred ﬁrst). OS (time since random
assignment to death from any cause) was an important
secondary end point; objective response rate (ORR; conﬁrmed complete and partial responses) and safety were
other secondary end points. Exploratory end points included duration of response (DOR), patient-reported outcomes,3 and time since random assignment to objective
tumor progression on next-line treatment or death from any
cause, whichever occurred ﬁrst.4

PATIENTS AND METHODS
Patients
As described previously,1 adult patients eligible for enrollment had untreated stage IV NSCLC with PD-L1 TPS
of 50% or greater, Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 1 or lower, measurable
disease per Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1,2 and life expectancy of 3 months or
longer. Patients were excluded if they had sensitizing EGFR
mutations, ALK translocations, untreated brain metastases,
or active autoimmune disease requiring systemic therapy
or were receiving systemic glucocorticoids or other immunosuppressive therapy.
Patients provided written informed consent. The protocol
(MK-3475-024-06) was approved by the institutional
review boards or independent ethics committees of the
participating institutions, and the trial was conducted in
accordance with Good Clinical Practice guidelines and the
Declaration of Helsinki.
Study Design
Eligible patients were randomly assigned (1:1; stratiﬁed
by ECOG PS of 0 v 1, squamous v nonsquamous histology,
East Asian v non–East Asian enrollment site) to receive
intravenous pembrolizumab (200 mg every 3 weeks) for 35
cycles (2 years) or investigator’s choice of platinum-based
chemotherapy (carboplatin plus pemetrexed, cisplatin plus
pemetrexed, carboplatin plus gemcitabine, cisplatin plus
gemcitabine, or carboplatin plus paclitaxel; pemetrexedcontaining regimens were only permitted for patients with
nonsquamous disease) for four to six cycles, in the absence
of radiologic disease progression (per RECIST), treatmentrelated adverse events (AEs) of unacceptable severity, or
patient withdrawal. Pemetrexed-containing chemotherapy
regimens and subsequent use of pemetrexed as maintenance therapy were permitted for patients with nonsquamous tumors. Patients assigned to chemotherapy
could cross over to pembrolizumab (starting 30 days or
more after last chemotherapy dose) if safety eligibility criteria were met; before the second interim analysis that

Assessments
As described previously,1 PD-L1 expression was assessed
in formalin-ﬁxed tumor samples (from core-needle or
excisional biopsy or tissue resected at time of diagnosis of
metastatic disease) using the PD-L1 IHC 22C3 pharmDx
assay (Agilent, Santa Clara, CA).5,6 Imaging studies were
performed every 9 weeks. Response was assessed per
RECIST version 1.1 by blinded, independent, central
radiology review (stopped after the second interim analysis
[protocol amendment 6]) and by investigator assessment.
Patients were contacted every 2 months during follow-up to
evaluate OS. All AEs occurring from random assignment
until 30 days after the last dose of study treatment (90 days
for serious AEs) were graded per the National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 4.0. The sponsor reviewed all AEs and condensed
several AE preferred terms that suggested an immunemediated etiology for speciﬁc categories, regardless of
investigator-assessed attribution of the event.
Statistical Analysis
The ﬁnal protocol-speciﬁed OS analysis was to occur after
approximately 170 patients had died, providing approximately 75% power to observe an HR of less than 1,
assuming approximately 70% of the patients in the chemotherapy arm crossed over to pembrolizumab. Because
OS beneﬁt was conﬁrmed at the second interim analysis
(data cutoff, May 9, 2016; 108 of 305 patients had died),
this ﬁnal analysis was not subjected to multiplicity control.
Efﬁcacy was assessed in the intent-to-treat population (all
randomly assigned patients), and safety was assessed in
the as-treated population (patients who were randomly
assigned and received one or more doses of study treatment, analyzed by treatment received). The Kaplan-Meier
method was used to estimate OS, with censoring of data for
patients alive or lost to follow-up at time of last contact.
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Between-group difference in OS was assessed using a
stratiﬁed log-rank test. HRs and associated 95% CIs were
assessed using a stratiﬁed Cox proportional hazards model
with Efron’s method of handling ties. Randomization
stratiﬁcation factors were applied to the stratiﬁed log-rank
and Cox models. After crossover to pembrolizumab, DOR
was summarized using the Kaplan-Meier method for
patients with conﬁrmed complete or partial responses in
this phase.
Additional analyses for OS, intended to complement the
intent-to-treat analysis, were conducted to estimate the
treatment difference between pembrolizumab and chemotherapy adjusted for crossover. The following three
statistical methods were applied: the simpliﬁed two-stage,
rank-preserving structural failure time (RPSFT), and
inverse probability of censoring weighting (IPCW) methods.
In stage 1 of the two-stage model (described by Latimer
et al7,8), a log-normal parametric survival model accounting
for important covariates was developed to estimate the
effect of crossover in the chemotherapy arm (acceleration
factor) that was then used to adjust survival times for
patients who crossed over to pembrolizumab. Patients were
eligible for inclusion in stage 1 if they met the following
criteria consistent with the clinical criteria for crossover
before the second interim analysis: centrally veriﬁed disease progression, no discontinuation of chemotherapy for
any reason other than progressive disease, ECOG PS of 0 or
1 at progression, survival of 30 days or longer after cessation of chemotherapy, and initiation of pembrolizumab
30 days or more after last chemotherapy dose. In the
second stage, observed survival times in the pembrolizumab arm were compared with adjusted survival
times in the chemotherapy arm and analyzed with a
stratiﬁed proportional hazards model. Bootstrapping was
used to estimate the 95% CI of the acceleration factor and
treatment effect HR.
In the RPSFT model,9,10 survival times of patients in the
chemotherapy arm who crossed over were adjusted
multiplicatively by an acceleration factor determined by
G-estimation to estimate the expected survival time if
patients had not crossed over. Survival times of all patients
randomly assigned to chemotherapy were recensored to
maintain the assumption of noninformative censoring.
Observed survival times in the pembrolizumab arm were
compared with adjusted survival times in the chemotherapy
arm using a Cox proportional hazards model. Bootstrapping
was used to estimate the 95% CIs of the HR.
The IPCW method addressed treatment crossover by
introducing artiﬁcial censoring at time of crossover for each
patient. To adjust for potential confounding from artiﬁcial
censoring, weights were calculated for observations before
crossover according to patient baseline and time-varying
demographic and disease-related characteristics (as
described by Latimer et al11). These were then used in a
weighted Cox proportional hazards model to estimate the

HR of pembrolizumab versus chemotherapy; the 95% CI
was estimated by bootstrapping.
RESULTS
Patients and Treatment
KEYNOTE-024 included 305 randomly assigned patients
(pembrolizumab, n = 154; chemotherapy, n = 151)
from 142 sites in 16 countries; all except one patient in
the chemotherapy arm received study treatment (Fig 1).
At data cutoff (July 10, 2017), median follow-up was
25.2 months (range, 20.4 to 33.7 months); 235 treated
patients across both arms had discontinued initially
assigned study treatment. Median treatment duration
was 7.9 months (range, 1 day to 28.8 months) in the
pembrolizumab arm and 3.5 months (range, 1 day to
30.5 months) in the chemotherapy arm. In the chemotherapy arm, 82 patients had crossed over to pembrolizumab on study; 15 additional patients received
anti–PD-1 treatment outside of the crossover (second line,
n = 12; third or later line, n = 3), for a crossover rate of
64.2% (97 of 151 patients) in the intent-to-treat population
and an effective crossover rate of 65.1% (97 of 149
patients) excluding patients remaining on therapy. Median
treatment duration for patients receiving on-study pembrolizumab crossover was 3.9 months (range, 1 day to
23.7 months; Fig 1). In the pembrolizumab arm, 56
patients went on to receive one or more subsequent
oncologic treatments, including surgery, radiation therapy,
chemotherapy, and immunotherapy (pembrolizumab,
n = 3; nivolumab, n = 5), after discontinuation. Patient
demographic and baseline clinical characteristics were
generally well balanced between the arms (Table 1).
Efﬁcacy Outcomes
At data cutoff, 169 patients had died (pembrolizumab, n =
73; chemotherapy, n = 96). Median OS was 30.0 months
(95% CI, 18.3 months to NR) in the pembrolizumab arm
and 14.2 months (95% CI, 9.8 to 19.0 months) in the
chemotherapy arm (HR, 0.63; 95% CI, 0.47 to 0.86; onesided nominal P = .002). Kaplan-Meier estimates of OS at
12 months for pembrolizumab and chemotherapy were
70.3% (95% CI, 62.3% to 76.9%) and 54.8% (95%
CI, 46.4% to 62.4%), respectively, with corresponding
24-month rates of 51.5% (95% CI, 43.0% to 59.3%) and
34.5% (95% CI, 26.7% to 42.4%; Fig 2A), respectively. An
OS beneﬁt for pembrolizumab compared with chemotherapy was observed in all subgroups evaluated (Fig 2B).
Efﬁcacy Outcomes in the On-Study Crossover Phase
Baseline characteristics for the 82 patients who crossed
over to on-study pembrolizumab were similar to those for
the overall study population (Appendix Table A1, online
only). Seventeen of 82 patients who crossed over had an
objective response per investigator assessment (ORR,
20.7%; 95% CI, 12.6% to 31.1%). Nineteen patients
(23.2%) had stable disease. Median time to response was

Journal of Clinical Oncology

Downloaded from ascopubs.org by University of Glasgow Library on April 29, 2019 from 130.209.006.061
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.

539

Reck et al

Patients randomly assigned
(N = 305)

Pembrolizumab

Chemotherapy

Patients assigned
(n = 154)
Patients treated
(n = 154)
Median treatment duration,
7.9 months (range, 1 day to 28.8 months)

Patients assigned
(n = 151)
Patients treated
(n = 150)
Median treatment duration,
3.5 months (range, 1 day to 30.5 months)

Treatment ongoing
Completed treatment
Discontinued
Progressive disease*
AEs
Died
Patient withdrew
Complete response
Physician decision

Treatment ongoing
Completed treatment
Discontinued
Progressive disease*
AEs
Died
Patient withdrew
Physician decision

(n = 23)
(n = 17)
(n = 114)
(n = 67)
(n = 30)
(n = 7)
(n = 7)
(n = 2)
(n = 1)

(n = 2)
(n = 27)
(n = 121)
(n = 76)
(n = 19)
(n = 9)
(n = 6)
(n = 11)

Crossed over to pembrolizumab on study

FIG 1. Disposition of patients in the
study. (*) Includes patients with
clinical progression or progressive
disease. AEs, adverse events; PD-1,
programmed death 1.

(n = 82)

Median treatment duration,
3.9 months (range, 1 day to 23.7 months)
+
Received anti–PD-1 outside of crossover
Received as second-line therapy
Received as third-line or later therapy

2.0 months (range, 1.1 to 8.4 months), and median DOR
was NR (range, 2.1 [ongoing] to 22.9 [ongoing] months)
after on-study crossover (Fig 3).
Crossover Adjustment
Seventy-seven patients randomly assigned to chemotherapy
met the prespeciﬁed criteria for inclusion in stage 1 of the
two-stage analysis (centrally veriﬁed progression, no discontinuation of chemotherapy other than for progressive
disease, ECOG PS of 0 or 1 at time of progression, and
survival of 30 days or more after cessation of chemotherapy).
This is less than the number of patients who qualiﬁed for onstudy crossover (n = 82), as described earlier, as a result of
the requirement for disease progression. Sixty-three of these
77 patients crossed over to pembrolizumab on study; 14 of
these patients did not, although four patients received
anti–PD-1 treatment outside the study (pembrolizumab,
n = 2; nivolumab, n = 2). The estimated acceleration factor
was 4.00 (95% CI, 1.59 to 11.30), indicating the survival
period after disease progression was reduced by 75% in the
chemotherapy arm versus unadjusted outcomes, resulting
in an adjusted median OS of 8.7 months (95% CI, 7.3 to
11.5 months). In stage 2, the adjusted HR for the adjusted
OS in the chemotherapy arm versus the observed OS in the
pembrolizumab arm was 0.49 (95% CI, 0.34 to 0.69; Fig
4). Similar results were obtained with the RPSFT and IPCW
methods; RPSFT-adjusted median OS was 11.8 months
(95% CI, 8.7 months to NR; adjusted HR, 0.52; 95% CI,

(n = 15)
(n = 12)
(n = 3)

0.33 to 0.75) and IPCW-adjusted median OS was 11.8
months (95% CI, 8.7 to 21.3 months; adjusted HR, 0.52;
95% CI, 0.33 to 0.80).
Toxicity
During treatment with initially assigned therapy, treatmentrelated AEs occurred in 76.6% (grade 3 to 5, 31.2%) and
90.0% (grade 3 to 5, 53.3%) of patients in the pembrolizumab and chemotherapy arms, respectively (Table 2).
Incidences of serious treatment-related AEs (22.7% and
20.7% in the pembrolizumab and chemotherapy arms,
respectively) and treatment discontinuation as a result of
treatment-related AEs (13.6% and 10.7% in the pembrolizumab and chemotherapy arms, respectively) were
similar between the arms. There were ﬁve treatment-related
fatal AEs (pembrolizumab, n = 2; chemotherapy, n = 3;
four were previously reported1 [pembrolizumab: sudden death
of unknown cause; chemotherapy: pulmonary sepsis,
pulmonary alveolar hemorrhage, and death of unknown
cause]). With longer follow-up in this analysis, there was
one additional death in the pembrolizumab arm (pneumonitis occurring on day 181 of pembrolizumab treatment
with signiﬁcant delay in start of immunosuppressive therapy).
The most frequent treatment-related AEs were diarrhea
(16.2%) and fatigue (14.3%) in the pembrolizumab arm
and anemia (44.0%) and nausea (43.3%) in the chemotherapy arm (Table 2). In the pembrolizumab arm, the most
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TABLE 1. Patient Demographic and Baseline Disease Characteristics
Pembrolizumab
(n = 154)

Chemotherapy
(n = 151)

64.5 (33-90)

66.0 (38-85)

Male

92 (59.7)

95 (62.9)

Female

62 (40.3)

56 (37.1)

0

54 (35.1)

53 (35.1)

1

99 (64.3)

98 (64.9)

2

1 (0.6)

Characteristic
Median age, years (range)
Sex

ECOG PS score

0 (0)

Region of enrollment
East Asia

21 (13.6)

19 (12.6)

133 (86.4)

132 (87.4)

29 (18.8)

27 (17.9)

125 (81.2)

124 (82.1)

Current

34 (22.1)

31 (20.5)

Former

115 (74.7)

101 (66.9)

Never

5 (3.2)

19 (12.6)

Treated brain metastases

18 (11.7)

10 (6.6)

Prior neoadjuvant therapy

3 (1.9)

1 (0.7)

Prior adjuvant therapy

6 (3.9)

3 (2.0)

Non–East Asia
Histology
Squamous*
Nonsquamous†
Smoking status

NOTE. Data presented as No (%), unless otherwise noted.
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance
status.
*Includes poorly differentiated squamous cell carcinoma (chemotherapy, n = 1).
†Includes adenosquamous (pembrolizumab, n = 2; chemotherapy, n = 2),
sarcomatoid (pembrolizumab, n = 3; chemotherapy, n = 2), and poorly
differentiated (pembrolizumab, n = 9; chemotherapy, n = 3) histologies.

common grade 3 to 5 treatment-related AEs were diarrhea
(3.9%) and pneumonitis (3.2%). Immune-mediated AEs and
infusion reactions, regardless of relationship to treatment,
occurred in 33.8% (grade 3 to 5, 13.6%) and 5.3% (grade 3
to 5, 0.7%) of patients in the pembrolizumab and chemotherapy arms, respectively (Table 2).
During crossover, the rates of any grade, grade 3 to 5, and
serious treatment-related AEs were 61.0%, 9.8%, and
8.5%, respectively (discontinuation rate due to treatmentrelated AEs, 6.1%). There were no grade 5 treatmentrelated AEs during on-study crossover. Among crossover
patients, 16 (19.5%) developed an immune-mediated AE
and/or infusion reaction (hypothyroidism, 9.8%; hyperthyroidism, 6.1%; pneumonitis, 4.9%; adrenal insufﬁciency, 1.2%; and infusion reaction, 1.2%).
DISCUSSION
In this updated analysis of KEYNOTE-024, pembrolizumab
continues to show an OS beneﬁt as ﬁrst-line therapy for

advanced NSCLC with PD-L1 TPS of 50% or greater
compared with platinum-based chemotherapy (HR, 0.63;
95% CI, 0.47 to 0.86; nominal P = .002). The improvement
in OS ﬁrst reported at the second interim analysis1 was
maintained despite signiﬁcant crossover to pembrolizumab
in the chemotherapy arm, with a notable median OS of
30.0 months for patients randomly assigned to pembrolizumab compared with 14.2 months for patients in the
chemotherapy arm. This efﬁcacy outcome is more favorable than that described in trials evaluating platinum-based
chemotherapy as ﬁrst-line treatment of NSCLC.12 To our
knowledge, KEYNOTE-024 is the ﬁrst study to show an
OS beneﬁt with anti–PD-1 monotherapy compared with
platinum-based chemotherapy as ﬁrst-line treatment in
patients with advanced NSCLC and has changed the
treatment paradigm of this disease.
With median exposure of 7.9 months in the pembrolizumab
arm at the time of analysis (more than double that in the
chemotherapy arm), pembrolizumab continues to demonstrate a favorable safety proﬁle. The incidence, severity,
and nature of AEs were consistent with those described
previously,1 with no evidence of cumulative toxicity with
longer exposure and no new safety signals when comparing
incidence of AEs during pembrolizumab treatment with
those among patients who received chemotherapy (notwithstanding the longer treatment duration with initial
therapy in the pembrolizumab arm). In the updated
analysis, there was one additional fatal immune-mediated
AE as a result of pneumonitis. Although median time to the
ﬁrst pneumonitis event was 100 days in the pembrolizumab
arm, this AE developed at day 181. Initially confused with
disease progression, immunosuppression was delayed
until after the patient underwent two separate biopsies.
Whereas at the second interim analysis 66 patients had
received pembrolizumab crossover therapy, at the time of
this analysis 82 patients had crossed over and 15 additional
patients had received subsequent anti–PD-1 therapy
(crossover rate, 64.2% in the intent-to-treat population;
effective crossover rate, 65.1% excluding patients remaining
on therapy). Outcomes in the crossover population are indicative of treatment beneﬁt for second-line pembrolizumab
monotherapy (ORR, 20.7%; median DOR, NR) and are
consistent with outcomes for patients with PD-L1 TPS of 50%
or greater in the phase III KEYNOTE-010 (ClinicalTrials.gov
identiﬁer: NCT01905657) study of pembrolizumab versus
docetaxel in patients with previously treated NSCLC.13
The high rate of crossover in this study (reﬂecting both the
study design and decision of the data and safety monitoring
committee to stop the trial analysis early) and apparent
activity of pembrolizumab during the crossover period likely
attenuated the observed OS effect. We used three statistical
methods to adjust for the inﬂuence of crossover on OS, and
all three supported an HR more strongly favoring the
pembrolizumab arm. The two-stage model was preferred,
as a result of evidence of deviation from the common
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FIG 2. (A) Kaplan-Meier analysis and
(B) subgroup analysis of overall survival (OS). Vertical dotted line in
subgroup analysis represents hazard
ratio (HR) in the overall population.
(*) Nominal P value. ECOG PS,
Eastern Cooperative Oncology Group
performance status; NR, not reached;
PD-1, programmed death 1.

HR (95% CI)

Overall
(N = 305)
Age, years
< 65 (n = 141)
65 (n = 164)
Sex
Male (n = 187)
Female (n = 118)
Enrollment region
East Asia (n = 40)
Non–East Asia (n = 265)
ECOG PS
0 (n = 107)
1 (n = 197)
Histology
Squamous (n = 56)
Nonsquamous (n = 249)
Smoking status
Current (n = 65)
Former (n = 216)
Never (n = 24)
Treated brain metastases
Yes (n = 28)
No (n = 277)
Chemotherapy regimen
With pemetrexed (n = 199)
Without pemetrexed (n = 106)

0.63 (0.47 to 0.86)
0.60 (0.38 to 0.96)
0.64 (0.42 to 0.98)
0.54 (0.36 to 0.79)
0.95 (0.56 to 1.62)
0.35 (0.12 to 1.01)
0.67 (0.49 to 0.93)
0.78 (0.44 to 1.37)
0.56 (0.39 to 0.81)
0.73 (0.38 to 1.39)
0.58 (0.41 to 0.83)
0.81 (0.41 to 1.60)
0.59 (0.41 to 0.85)
0.90 (0.11 to 7.59)
0.73 (0.20 to 2.62)
0.64 (0.46 to 0.88)
0.66 (0.45 to 0.97)
0.56 (0.33 to 0.95)

0.1

1

10

Pembrolizumab better Chemotherapy better

HR (95% CI)

treatment effect assumed in RPSFT and because the IPCW
method is more prone to bias in the presence of relatively
small sample sizes.7,11 Overall, the crossover-adjusted
analyses complement the primary efﬁcacy analysis and
reinforce the potential to improve outcomes with early use
of pembrolizumab as ﬁrst-line treatment.
Given the OS and PFS beneﬁts observed in KEYNOTE-024,
pembrolizumab remains the only checkpoint inhibitor

approved in the ﬁrst-line setting as monotherapy for
patients with PD-L1 TPS of 50% or greater. Recently,
results from the KEYNOTE-042 (ClinicalTrials.gov identiﬁer:
NCT02220894) study conﬁrmed and extended those from
KEYNOTE-024 by demonstrating signiﬁcantly improved OS
with pembrolizumab versus platinum-based chemotherapy
not only in treatment-naive patients with PD-L1 TPS of 50%
or greater (HR, 0.69; 95% CI, 0.56 to 0.85; P = .0003), but
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FIG 3. Kaplan-Meier analysis of duration of response per investigator
assessment in patients who crossed over from chemotherapy to
on-study pembrolizumab (ie, duration of response for responses
occurring after day 1 of crossover treatment cycle 1). (*) Plus sign
indicates that the response duration is censored. NR, not reached.

also in those with PD-L1 TPS of 20% or greater (HR, 0.77;
95% CI, 0.64 to 0.92; P = .002) and 1% or greater (HR, 0.81;
95% CI, 0.71 to 0.93; P = .0018).14 In contrast, administration
of nivolumab 3 mg/kg every 2 weeks in the CheckMate 026
(ClinicalTrials.gov identiﬁer: NCT02041533) study did not
improve PFS or OS among patients with previously untreated
advanced NSCLC with PD-L1 expression of 5% or greater.15
Although cross-trial comparisons should be approached with
caution, different PD-L1 assays (with different anti–PD-L1
antibodies) and thresholds were used in CheckMate 026
relative to KEYNOTE-024 and KEYNOTE-042, which may, in
part, explain the opposing outcomes.16

70.3
54.8
40.3

Pembrolizumab with platinum chemotherapy has been
evaluated in several trials. In the randomized cohort G of
the phase I/II KEYNOTE-021 (ClinicalTrials.gov identiﬁer:
NCT02039674) study, pembrolizumab plus carboplatin and
pemetrexed in patients with newly diagnosed, advanced,
nonsquamous NSCLC without EGFR/ALK alterations irrespective of PD-L1 TPS demonstrated improved ORR and PFS
compared with carboplatin and pemetrexed alone,17 leading
to approval in the United States. The phase III KEYNOTE-189
(ClinicalTrials.gov identiﬁer: NCT 02578680) study evaluated
ﬁrst-line pembrolizumab plus pemetrexed and platinum in
patients with nonsquamous metastatic NSCLC irrespective of
PD-L1 tumor expression and showed signiﬁcant improvement
in OS (HR, 0.49; 95% CI, 0.38 to 0.64; P , .001) and PFS
(HR, 0.52; 95% CI, 0.43 to 0.64; P , .001) compared with
placebo plus chemotherapy.18 Pembrolizumab in combination
with carboplatin and paclitaxel or nab-paclitaxel resulted in
improved OS and PFS compared with placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with
squamous histology regardless of PD-L1 expression (OS HR,
0.64; 95% CI, 0.49 to 0.85; P , .001; PFS HR, 0.56; 95%
CI, 0.45 to 0.70; P , .001) in the phase III KEYNOTE-407
(ClinicalTrials.gov identiﬁer: NCT02775435) study. 19
Together with our current analyses, these data show
that for all patients with advanced NSCLC without EGFR/
ALK alterations, a ﬁrst-line treatment regimen containing
pembrolizumab (either as monotherapy or in combination
with platinum chemotherapy) is available that can improve
OS compared with platinum doublet chemotherapy.
In addition, other anti–programmed death 1 or anti–PD-L1
antibodies have been evaluated in combination with
chemotherapy or immunotherapy in patients with NSCLC.
Atezolizumab with bevacizumab, carboplatin, and paclitaxel
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TABLE 2. Adverse Events in the As-Treated Population
No. of Patients (%)
Adverse Event

Pembrolizumab (n = 154)

Chemotherapy (n = 150)

Treatment-related AEs†
Any grade

118 (76.6)

135 (90.0)

Grade 3-5

48 (31.2)

80 (53.3)

Serious

35 (22.7)

31 (20.7)

Led to discontinuation

21 (13.6)

16 (10.7)

Led to death

2 (1.3)

Treatment-related AEs occurring in $ 10% of patients in
either arm‡

3 (2.0)

Any Grade

Grade 3 or 4*

Diarrhea

25 (16.2)

6 (3.9)

21 (14.0)

Fatigue

22 (14.3)

3 (1.9)

43 (28.7)

Pyrexia

18 (11.7)

0

9 (6.0)

0

Pruritus

18 (11.7)

0

3 (2.0)

0

Rash

16 (10.4)

2 (1.3)

3 (2.0)

0

Nausea

15 (9.7)

0

Decreased appetite

15 (9.7)

0

39 (26.0)

4 (2.7)

2 (1.3)

66 (44.0)

29 (19.3)

Anemia

8 (5.2)

Any Grade

65 (43.3)

Grade 3 or 4*
2 (1.3)
5 (3.3)

3 (2.0)

Constipation

6 (3.9)

0

17 (11.3)

0

Blood creatinine increased

5 (3.2)

0

16 (10.7)

0

Vomiting

4 (2.6)

0

30 (20.0)

0

Stomatitis

4 (2.6)

0

18 (12.0)

2 (1.3)

Neutropenia

1 (0.6)

0

33 (22.0)

20 (13.3)

Neutrophil count decreased

1 (0.6)

0

21 (14.0)

7 (4.7)

WBC count decreased

1 (0.6)

0

17 (11.3)

4 (2.7)

Dysgeusia

1 (0.6)

0

16 (10.7)

0

Platelet count decreased

0

0

18 (12.0)

10 (6.7)

Thrombocytopenia

0

AEs with possible immune etiology occurring in $ 0% of
patients

Any Grade

0
Grade 3 or 4§

Any

52 (33.8)

20 (13.2)

Hypothyroidism

16 (10.4)

Pneumonitis

12 (7.8)

Hyperthyroidism

11 (7.1)

16 (10.7)
Any Grade

8 (5.3)
Grade 3 or 4§

8 (5.3)

1 (0.7)

0

3 (2.0)

0

4 (2.6)

1 (0.7)

1 (0.7)

0

2 (1.3)

0

Infusion reactions

8 (5.2)

1 (0.6)

2 (1.3)

0

Severe skin reactions

8 (5.2)

8 (5.2)

0

0

Colitis

6 (3.9)

3 (1.9)

0

0

Thyroiditis

4 (2.6)

0

0

0

Myositis

3 (1.9)

0

0

0

Hepatitis

1 (0.6)

1 (0.6)

0

0

Hypophysitis

1 (0.6)

1 (0.6)

0

0

1 (0.6)

1 (0.6)

0

0

Nephritis

(continued on following page)
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TABLE 2. Adverse Events in the As-Treated Population (continued)
No. of Patients (%)
Adverse Event

Pembrolizumab (n = 154)

Chemotherapy (n = 150)

Pancreatitis

1 (0.6)

1 (0.6)

0

0

Type 1 diabetes

1 (0.6)

1 (0.6)

0

0

Uveitis

1 (0.6)

1 (0.6)

0

0

NOTE. The as-treated population included all patients who were randomly assigned and received one or more doses of a trial treatment. Adverse events that
occurred during crossover from the chemotherapy arm to pembrolizumab are excluded.
Abbreviation: AEs, adverse events.
*Two grade 5 treatment-related adverse events occurred in the pembrolizumab arm (pneumonitis and sudden death) and three in the chemotherapy arm
(death, pulmonary sepsis, and pulmonary alveolar hemorrhage).
†Events were attributed to treatment by the investigator and are listed as indicated by the investigator on the case report form. Although decreased
neutrophil count and neutropenia may reﬂect the same condition, they were listed by the investigators as two distinct events; this is also the case for decreased
platelet count and thrombocytopenia.
‡Events are listed in descending order of frequency in the total population.
§One grade 5 immune-mediated AE occurred in the pembrolizumab arm (pneumonitis).

improved OS (HR, 0.78; 95% CI, 0.64 to 0.96; P = .02) and
PFS (HR, 0.62; 95% CI, 0.52 to 0.74; P , .001) compared
with bevacizumab, carboplatin, and paclitaxel in patients with
nonsquamous histology,20 and atezolizumab with carboplatin
and nab-paclitaxel improved median PFS (HR, 0.715; 95%
CI, 0.603 to 0.848; P = .0001) but not OS (HR, 0.96; 95% CI,
0.78 to 1.18; P = .6931) compared with carboplatin plus nabpaclitaxel in patients with squamous NSCLC.21 Nivolumab
with chemotherapy improved PFS compared with chemotherapy alone in patients whose tumors did not express PD-L1
(HR, 0.74; 95% CI, 0.58 to 0.94).22 Finally, nivolumab plus
ipilimumab demonstrated longer PFS compared with chemotherapy (HR, 0.83; 95% CI, 0.72 to 0.96), particularly in

patients with high tumor mutational burden (HR, 0.58; 97.5%
CI, 0.41 to 0.81).23 At present, tumor mutational burden does
not have a role in guiding treatment decisions, because an OS
beneﬁt has not been shown.
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greater and without EGFR/ALK alterations.
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APPENDIX
TABLE A1. Demographic and Baseline Disease Characteristics Among Patients
Who Crossed Over to On-Study Pembrolizumab
No. of Crossover Patients
Characteristic
(n = 82)
Median age, years (range)

65.0 (40-83)

Sex
Male

47 (57.3)

Female

35 (42.7)

ECOG PS score
0

37 (45.1)

1

45 (54.9)

Region of enrollment
East Asia

10 (12.2)

Non–East Asia

72 (87.8)

Histology
Squamous

18 (22.0)

Nonsquamous*

64 (78.0)

Smoking status
Current

15 (18.3)

Former

52 (63.4)

Never

15 (18.3)

Treated brain metastases

3 (3.7)

Prior neoadjuvant therapy

0

Prior adjuvant therapy

3 (3.7)

NOTE. Data presented as No (%), unless otherwise noted.
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance
status.
*Includes adenosquamous (n = 1), sarcomatoid (n = 2), and poorly differentiated
(n = 1) histologies.
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